A
Anika Therapeutics, Inc. (ANIK)
NMS – Real Time Price. Currency in USD
14.28
-0.47 (-3.19%)
At close: Mar 27, 2026, 4:00 PM EDT
14.61
+0.33 (2.34%)
After-hours: Mar 27, 2026, 5:20 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
14.28
-0.47 (-3.19%)
At close: Mar 27, 2026, 4:00 PM EDT
14.61
+0.33 (2.34%)
After-hours: Mar 27, 2026, 5:20 PM EDT
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Name | Position |
|---|---|
| Dr. Cheryl Renee Blanchard Ph.D. | Executive Chair |
| Mr. Ben Joseph | Vice President of Commercial & Corporate Development |
| Mr. David Colleran J.D. | Executive VP, General Counsel & Corporate Secretary |
| Mr. Ian W. McLeod | VP, Chief Accounting Officer & Treasurer |
| Mr. James Chase | Senior Vice President of International Sales & Marketing |
| Mr. Mark Namaroff | Vice President of Investor Relations, ESG & Corporate Communications |
| Mr. Matthew Hall | Director of Corporate Development & Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-03-03 | 10-K | anik20251231_10k.htm |
| 2026-01-08 | 8-K | d136217d8k.htm |
| 2025-11-05 | S-8 | fs8_110425.htm |
| 2025-07-30 | 8-K | f8k_072925.htm |
| 2025-07-17 | CORRESP | filename1.htm |
| 2025-06-24 | 8-K | f8k_062425.htm |
| 2025-05-09 | 8-K | f8k_050925.htm |
| 2025-04-28 | ARS | edge20045980x3_ars.pdf |
| 2025-04-10 | 8-K | f8k_041025.htm |
| 2025-03-17 | 10-K | anik20241231_10k.htm |
| Mr. Stephen D. Griffin | President, Principal Financial Officer, CEO & Director |
| Ms. Lisa Funiciello | Vice President of Human Resources |
| Ms. Mira Leiwant | Senior Vice President of Regulatory, Quality & Clinical Affairs |